摘要:
A silver halide photographic light-sensitive material which comprises a support having thereon a light-sensitive silver halide emulsion layer, wherein the photographic light-sensitive material contains a blocked photographic agent therein represented by formula (I): ##STR1## wherein A represents a photographic agent moiety which is bonded to a blocking moiety through a hetero atom or a group which is bonded to a blocking moiety through a hetero atom and capable of releasing a photographic agent upon a subsequent reaction after the group is released; Y represents a hydrogen atom or a substituent; and Z represents an atomic group necessary to form a carbocyclic ring or a heterocyclic ring.The precursor of photographic agent is completely stable during the preservation of the photographic light-sensitive material and releases a photographic agent at a desired time upon the processing of the photographic light-sensitive material. The precursor also exhibits its function to a substantial degree over a wide range of pH.
摘要:
A silver halide photographic material which comprises a support having coated thereon a light-sensitive silver halide emulsion layer, wherein the photographic material contains a blocked photographic agent represented by the following general formula (I): ##STR1## wherein A represents a photographic agent moiety which is bonded to a blocking moiety through a hetero atom, or a precursor thereof; R.sup.1 represents a hydrogen atom or a substituent group; and Z represents atoms necessary to form a carboxylic ring or a heterocyclic ring. The blocked photographic agent is completely stable upon storage of the photographic material, and releases a photographic agent at a desired time upon processing of the photographic material. The blocked photographic agent also exhibits its function to a substantial degree over a wide range.
摘要:
A silver halide photosensitive material is described, comprising a support and at least one silver halide emulsion layer, wherein said emulsion layer or another layer contains a compound represented by formula (I) ##STR1## wherein X represents an atomic group forming a redox center of benzene type having substituents by linking with C.sub.A and C.sub.B, and which does not enable Time-PUG to be released until the redox center is oxidized during development processing; EWG represents an electron withdrawing group having a Hammet's .sigma. para value exceeding 0.3; C.sub.A and C.sub.B each represents a carbon atom; R.sub.1 and R.sub.2 each represents a hydrogen atom or a suitable substituent; Time represents a timing group connecting to C.sub.B through a sulfur, nitrogen, or selenium atom thereof, t is an integer of 0 or 1, and when t=0, Time is a chemical bond; PUG represents a photographically useful group and connects to C.sub.B through a sulfur, nitrogen, or selenium atom thereof when t=0; and n is an integer of 0 or 1.
摘要:
This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.
摘要:
This invention relates to compounds having a formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug or polymorph thereof wherein X is —C(Rg)═N-A. The invention also relates to methods of treating IL-12 overproduction-related disorders, methods of treating or preventing disorders related with excessive bone loss, methods for inhibiting osteoclast formation, and methods for treating or preventing a disorder associated with excessive bone resorption.
摘要:
Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—.R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R7 and Rg are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and Rg is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.Z is ═O or ═S.Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.
摘要翻译:公开了由结构式(I)表示的化合物:Y是共价键,亚苯基或取代或未取代的直链烃基。 此外,Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。 优选Y为共价键或-C(R 7 R 8) - 。 R 1和R 2独立地是芳基或取代的芳基,R 3和R 4独立地是-H,脂族基团,取代的脂族基团,芳基或取代的芳基。 R5-R6独立地是-H,脂族基团,取代的脂族基团,芳基或取代的芳基。 R7和Rg各自独立地为-H,脂族或取代的脂族基团,或R7为-H,Rg为取代或未取代的芳基,或者R7和R8一起为C2-C6取代或未取代的亚烷基 。 Z为═O或═S。 还公开了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。 还公开了通过向受试者施用结合式(I)的化合物与紫杉醇或紫杉醇的类似物组合来治疗患有癌症的受试者的方法。
摘要:
This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.
摘要:
This invention features a method of making hop powder containing stable alkaline salts of hop bitter acids and an edible carrier. Also within the scope of this invention is a hop product containing alkaline salts of hop bitter acids and an edible carrier.
摘要:
Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): The thiohydrazide product compound is represented by Structural Formula (II): In Structural Formulas (I)-(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R2 is an aryl group or a substituted aryl group, then R5 is a hydrazine protecting group; and when R2 is an aliphatic or substituted aliphatic group, then R5 is —H or a hydrazine protecting group. R10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.